Abstracts tagged "Systemic sclerosis"

Abstract Number: 1232 • ACR Convergence 2023
Improvement Across Organ System, Physician and Patient Reported Outcome Measures over a 36-time Period in the Juvenile Systemic Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Kathryn Torok⁵, Brian Feldman⁶, Maria Teresa TErreri⁷, Ana Sakamoto⁸, Jordi Anton⁹, Simone Appenzeller¹⁰, Edoardo Marrani¹¹, Maria Katsikas¹², Maria Jose Santos¹³, FLAVIO SZTAJNBOK¹⁴, Lillemor Berntson¹⁵, Juergen Brunner¹⁶, Sindhu Johnson¹⁷, Mikhail Kostik¹⁸, Kirsten Minden¹⁹, Farzana Nuruzzaman²⁰ and Nicola Helmus²¹, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁴Istanbul University - Cerrahpasa, Istanbul, Turkey, ⁵University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷UNIFESP, São Paulo, Brazil, ⁸Federal University of São Paulo (UNIFESP), São Paulo, Brazil, ⁹Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ¹⁰UNICAMP, Campinas, Brazil, ¹¹University of Florence, Firenze, Italy, ¹²Hospital de Pediatria Juan P Garrahan, Servicio de Inmunologia/Reumatologia, Buenos Aires, Argentina, ¹³Hospital Garcia de Orta, Almada, Lisboa, Portugal, ¹⁴UFRJ/UERJ, São Paulo, Brazil, ¹⁵Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ¹⁶Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ¹⁷Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ¹⁸Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁹Charité University Medicine and German Rheumatism Research Center Berlin, Berlin, Germany, ²⁰Stony Brook Children's Hospital, Stony Brook, NY, ²¹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1, 000, 000 children. The Juvenile Systemic Scleroderma Inception cohort…
Abstract Number: 1664 • ACR Convergence 2023
Fibroblast Specific Interferon Regulatory Factor 7 (IRF7) Expression Is a Key Link Between Type I Interferon Activation and the Exaggerated Dermal and Pulmonary Fibrosis in Systemic Sclerosis
Minghua Wu¹, Jerry Alonso², Julio charles², Brian Skaug², Tingting Mills³, Maureen Mayes² and Shervin Assassi⁴, ¹Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ²Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ³Biochemistry Department, University of Texas McGovern Medical School, Houston, TX, ⁴University of Texas McGovern Medical School at Houston, Houston, TX
Background/Purpose: A prominent interferon (IFN) activation signature has been observed at the peripheral blood and end-organ levels in systemic sclerosis (SSc). However, the mechanisms by…
Abstract Number: 2357 • ACR Convergence 2023
The Involvement of CCR3-CCL24 Axis in Endothelial to Mesenchymal Transition Process and Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
Itzchak Amoyal¹, Tzipi Hornik-Lurie², Tali Zitman-Gal¹, Hilit Levy³, Ilan Vaknin³, Liat Drucker⁴, Ishai Heusler⁵, Yair Levy¹ and Shelly Tartakover Matalon¹, ¹Meir Medical Center, Autoimmune Research Laboratory, Kfar-Saba, Israel, ²Meir Medical Center, Data Research Department, Kfar-Saba, Israel, ³Chemomab Ltd, Tel Aviv, Israel, ⁴Meir Medical Center, Oncogenetics Laboratory, Kfar Saba, Israel, ⁵Meir Medical Center, Department of Obstetric and Genecology, Kfar-Saba, Israel
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular injury and extensive tissue fibrosis of the skin and internal organs. Endothelial cells (ECs),…
Abstract Number: 0611 • ACR Convergence 2023
Demographics and Clinical Features Associated with Small Bowel Hypomotility in Systemic Sclerosis
Jenice Cheah¹, Jamie Perin², Michael Hughes³, Julie Paik⁴, Christopher Mecoli², Laura Hummers⁴, Ami Shah⁵, Fred Wigley⁶ and Zsuzsanna McMahan⁷, ¹University of California Los Angeles, Los Angeles, CA, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ⁴Johns Hopkins University, Baltimore, MD, ⁵Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ⁶Department of Rheumatology, Johns Hopkins Medicine, Baltimore, MD, ⁷Johns Hopkins Rheumatology, Lutherville, MD
Background/Purpose: The gastrointestinal (GI) tract is the second most commonly affected organ in patients with systemic sclerosis (SSc). It is estimated that the small bowel…
Abstract Number: 0628 • ACR Convergence 2023
Interstitial Lung Disease in Very Early Systemic Sclerosis
Sinziana Muraru¹, Carina Mihai¹, Anna-Maria Hoffmann-Vold², Cosimo Bruni¹, Muriel Elhai³, Mike Becker⁴, Suzana Jordan¹, Alexandru Garaiman¹, Oliver Distler¹ and Rucsandra Dobrota¹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) affects around 50% of patients with systemic sclerosis (SSc) and is the main cause of mortality. Preliminary data from small…
Abstract Number: 0650 • ACR Convergence 2023
Understanding the Employment Landscape in People with Systemic Sclerosis
Hila Jazayeri¹, Zareen Ahmad¹, Monique Gignac² and Sindhu Johnson³, ¹University of Toronto, Toronto, ON, Canada, ²Institute for Work & Health, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is a systemic rheumatic disease that restricts participation in various life roles, including in the workplace. Our objectives were to identify…
Abstract Number: 0672 • ACR Convergence 2023
Risk of New-onset Depression in Patients with Systemic Sclerosis : A Nationwide Population-based Study
Hahee Son and Su-Jin Moon, Yeouido St. Mary's Hospital, Catholic University of Korea, Seoul, South Korea
Background/Purpose: Systemic sclerosis (SSc) is a rare chronic inflammatory disease characterized by vasculopathy, autoimmunity and progressive fibrosis in various organs. The patients with SSc are…
Abstract Number: 0946 • ACR Convergence 2023
Immunoglobulins G Purified from Systemic Sclerosis Patients Influence Cytoplasmic and Nuclear Proteins Profile in Dermal Fibroblasts
Aurélien Chepy¹, Marie Duhamel², Solange Vivier¹, Clément Chauvet¹, Lucile Guilbert³, Eric Hachulla⁴, Sylvain Dubucquoi¹, David Launay¹, Michel Salzet² and Vincent Sobanski¹, ¹Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, ²Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, ³CHU Lille, Institut d’Immunologie, Lille, France, ⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France
Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc). While recognized as potent biomarkers, their pathogenic role is unclear. Recently, we showed that immunoglobulins G…
Abstract Number: 1233 • ACR Convergence 2023
The Pattern of Medication Use Significantly Changed over 36 Months Observation Period. Result from the Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Brian Feldman⁵, Kathryn Torok⁶, Maria Teresa TErreri⁷, Ana Sakamoto⁸, Jordi Anton⁹, Simone Appenzeller¹⁰, Edoardo Marrani¹¹, Maria Jose Santos¹², FLAVIO SZTAJNBOK¹³, Lillemor Berntson¹⁴, Juergen Brunner¹⁵, Mikhail Kostik¹⁶, Farzana Nuruzzaman¹⁷ and Nicola Helmus¹⁸, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁴Istanbul University - Cerrahpasa, Istanbul, Turkey, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷UNIFESP, São Paulo, Brazil, ⁸Federal University of São Paulo (UNIFESP), São Paulo, Brazil, ⁹Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ¹⁰UNICAMP, Campinas, Brazil, ¹¹University of Florence, Firenze, Italy, ¹²Hospital Garcia de Orta, Almada, Lisboa, Portugal, ¹³UFRJ/UERJ, São Paulo, Brazil, ¹⁴Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ¹⁵Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ¹⁶Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁷Stony Brook Children's Hospital, Stony Brook, NY, ¹⁸Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1,000,000 children. Currently no medications are licensed for the treatment…
Abstract Number: 1665 • ACR Convergence 2023
Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis
Hanlin Yin¹, Oliver Distler², Bin Li³, Qingran Yan⁴ and Liangjing Lu¹, ¹Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Shanghai institute of immunology, Shanghai, China, ⁴Department of Rheumatology, Renji Hospital, Shanghai Jiaotong Univeisty School of medcine, Shanghai, China
Background/Purpose: Type I interferon (IFN-1) signature is a hallmark of patients with systemic sclerosis (SSc). However, its significance in clinical stratification and contribution to deterioration…
Abstract Number: 2359 • ACR Convergence 2023
Reversal of the Activation State of Pro-fibrotic CD206 Positive Macrophages by Therapeutic Peptide AUR300 in Systemic Sclerosis
Sandra Lopez¹, Bahja Ahmed Abdi¹, Linda Lei¹, Anas Al-Oweidi¹, Claire Macfadyen¹, Lydia Nagib¹, Sarah Ive¹, Anshul Kumar¹, Teresa Collins¹, Jennifer Cross², Christopher Denton¹, David Abraham¹, Clayton Yates³, Charles Garvin⁴, Henry Lopez⁴, George Martin⁵ and Richard Stratton¹, ¹University College London, London, United Kingdom, ²Aurinia Pharmaceuticals Inc., Rockford, MD, ³Tuskegee University, Tuskegee, AL, ⁴Riptide Bioscience Inc., Valejo, CA, ⁵Riptide Bioscience Inc., Bethesda, MD
Background/Purpose: A spectrum of macrophage activation is seen in human pathologic conditions; M2-like CD206 positive macrophages are pro-fibrotic and proresolution, while M1-like macrophages are proinflammatory,…
Abstract Number: 0612 • ACR Convergence 2023
COVID Vaccinations and Infections Among Individuals with Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study
Kimberly Lakin¹, Jessica Gordon¹, Yin Wu², Linda Kwakkenbos³, Marie-Eve Carrier², Richard Henry², Christopher Denton⁴, Luc Mouthon⁵, Robert Spiera⁶ and Brett Thombs², ¹Hospital for Special Surgery, New York, NY, ²Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada, ³Radboud University, Nijmegen, Netherlands, ⁴University College London, London, United Kingdom, ⁵Hopital Cochin - Paris University, Paris, France, ⁶Hosptial for Special Surgery, New York, NY
Background/Purpose: We previously surveyed individuals with systemic sclerosis (SSc) enrolled in Scleroderma Patient-centered Intervention Network (SPIN) Cohort between April-May 2021 to determine COVID-19 vaccination rates,…
Abstract Number: 0630 • ACR Convergence 2023
Prevalence and Risk Factors for Systemic Sclerosis Digital Ischemic Complications in the Collaborative National Quality and Efficacy Registry
Marissa Savoie¹, Monica Harding², Jessica Alvey², John VanBuren², Shervin Assassi³, Elana Bernstein⁴, Lorinda Chung⁵, Luke Evnin⁶, Tracy Frech⁷, Jessica Gordon⁸, Faye Hant⁹, Laura Hummers¹⁰, Dinesh Khanna¹¹, Kimberly Lakin⁸, Dorota Lebiedz-Odrobina¹², Yiming Luo¹³, Ashima Makol¹⁴, Jerry Molitor¹⁵, Duncan Moore¹⁶, Carrie Richardson¹⁷, Nora Sandorfi¹⁸, Ami Shah¹⁹, Ankoor Shah²⁰, Brian Skaug²¹, Virginia Steen²², Elizabeth Volkmann²³ and Flavia Castelino¹, ¹Massachusetts General Hospital, Boston, MA, ²University of Utah, Salt Lake City, UT, ³University of Texas McGovern Medical School at Houston, Houston, TX, ⁴Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ⁵Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁶Scleroderma Research Foundation, Brisbane, CA, ⁷Vanderbilt University Medical Center, Nashville, TN, ⁸Hospital for Special Surgery, New York, NY, ⁹Medical University of South Carolina, Charleston, SC, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹University of Michigan, Ann Arbor, MI, ¹²University of Utah, Cottonwood Heights, UT, ¹³Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, ¹⁴Mayo Clinic, Rochester, MN, Rochester, MN, ¹⁵University of Minnesota, Minneapolis, MN, ¹⁶Northwestern University, Department of Rheumatology, Chicago, IL, ¹⁷Northwestern University, Chicago, IL, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ²⁰Duke University, Durham, NC, ²¹Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ²²Georgetown University School of Medicine, Washington, DC, ²³University of California Los Angeles, Los Angeles, CA
Background/Purpose: Digital ischemic ulcers (DIU) develop in 36-44% of patients with systemic sclerosis (SSc).1,2Prior international observational studies have evaluated characteristics of digital pitting and ulcers…
Abstract Number: 0651 • ACR Convergence 2023
Abnormal Nailfold Video-capillaroscopy Is Independently Associated with non-UIP Radiographic Patterns in Autoimmune ILD: A Multicenter Study from the NEREA Registry
Jesus Loarce-Martos¹, Hilda Godoy², Laura Cebrian³, M Jesus Rodriguez-Nieto⁴, Juan Rigual⁵, Rosalía Laporta², Belen Lopez-Muñiz³, lydia Abasolo⁶, Olga Sanchez Pernaute⁷ and Fredeswinda Romero⁷, ¹Ramón y Cajal University Hospital, Madrid, Spain, ²Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Hospital Universitario Infanta Leonor, Madrid, Spain, ⁴Pulmonology department, Hospital Fundación Jimenez Díaz, Madrid, Spain, ⁵Pulmonology department, Hospital Ramón y Cajal,, Madrid, Spain, ⁶Hospital Clínico San Carlos, Madrid, Spain, ⁷IIS-HU Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: The aim of this study is to describe the nailfold video-capillaroscopy (NVC) findings in patients with interstitial lung disease associated to connective tissue diseases…
Abstract Number: 0783 • ACR Convergence 2023
Tolerability of CAR T Cell Therapy in Autoimmune Disease
Jule Taubmann¹, Fabian Müller², Michael Aigner³, Ioanna Minopoulou⁴, Johannes Knitza⁵, Dagmar Werner⁶, Christina Bergmann⁷, Gerhard Kroenke⁸, Andreas Mackensen³ and Georg Schett⁶, ¹Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ²Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, ⁵Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁶FAU Erlangen-Nürnberg, Erlangen, Germany, ⁷Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁸Charite Berlin, Berlin, Germany
Background/Purpose: We have previously shown that CD19 CAR T cell therapy can lead to improvement of severe forms of B cell mediated autoimmune disease including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.